Antiretroviral drug interactions: Often unrecognized, frequently unavoidable, sometimes unmanageable

Journal of Antimicrobial Chemotherapy

Volumn 64, Issue 1, 2009, Pages 5-8

  Seden, Kay ^a,b   Back, David ^b   Khoo, Saye ^b  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

HIV AIDS; Non nucleoside reverse transcriptase inhibitors; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; ELVITEGRAVIR; LOPINAVIR; PROTEINASE INHIBITOR; RALTEGRAVIR; RIBAVIRIN; RIFAMPICIN; RITONAVIR; ROSUVASTATIN;

ANTIVIRAL THERAPY; DEVELOPING COUNTRY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DISPOSITION; DRUG DRUG INTERACTION; DRUG EFFICACY; DRUG INTERACTION; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; HEALTH CARE DELIVERY; HEALTH PROGRAM; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MIXED INFECTION; POLYPHARMACY; PRESCRIPTION; RISK FACTOR; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ANTI-RETROVIRAL AGENTS; DATABASES, FACTUAL; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS;

EID: 67249132363     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp152     Document Type: Editorial

References (24)

1. Rastegar D, Knight A, Monolakis J. Antiretroviral errors among hospitalised patients with HIV infection. Clin Infect Dis 2006; 43: 933-8.
2. Shah S, McGowan J, Opulski B et al. Identification of drug interactions involving ART in New York City HIV specialty clinics. In: Abstracts of the Fourteenth Conference on Retroviruses and Opportunistic Infections, Los Angeles, CA, 2007. Abstract 573, p. 277. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
3. De Maat M, De Boer A, Koks C et al. Evaluation of clinical pharmacist interventions on drug interactions in outpatient pharmaceutical HIV-care. J Clin Pharm Ther 2004; 29: 121-30.
4. Sanderson N. Drug-drug interactions: The silent epidemic. Psychiatr Serv 2005; 56: 22-4.
5. Miller C, El-Kholi R, Faragon J et al. Prevalence and risk factors for clinically significant drug interactions with antiretroviral therapy. Pharmacotherapy 2007; 27: 1379-86.
6. Mathias A, West S, Hui J et al. Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure. Clin Pharmacol Ther 2009; 83: 64-70.
7. Kiser J, Gerber J, Predhomme J et al. Drug/drug interaction between lopinavir/ritonavir and rosuvastatin in healthy volunteers. J Acquir Immune Defic Syndr 2008; 47: 570-8.
8. WHO. Global Tuberculosis Control: Surveillance, Planning, Financing Twelfth Annual Report of the World Health Organization, Geneva, 2008. http://www.who.int/tb/publications/global_report/en/ (3 February 2009, date last accessed).
9. Friedland G, Khoo S, Jack C et al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58: 1299-302.
10. Stohr W, Back D, Dunn D et al. Factors influencing efavirenz and nevirapine plasma concentration: Effect of ethnicity, weight and co-medication. Antivir Ther 2008; 13: 675-85.
11. UNAIDS Joint United Nations Programme on HIV/AIDS. 2008 Report on the Global AIDS Epidemic. http://www.unaids.org/en/KnowledgeCentre/ HIVData/GlobalReport/2008/2008_Global_report.asp (3 February 2009, date last accessed).
12. Thompson A, Patel K, Tillman H et al. Directly acting antivirals for the treatment of patients with hepatitis C infection: A clinical development update addressing key future challenges. J Hepatol 2009; 50: 184-94.
13. Kempf D, Klein C, Chen H et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007; 18: 163-7.
14. DeLorenze G, Follansbee S, Nguyen D et al. Medication error in the care of HIV/AIDs patients-electronic surveillance, confirmation and adverse events. Med Care 2005; 43 Suppl 9: 63-8.
15. Nguyen N, Holodniy M. HIV infection in the elderly. Clin Interv Aging 2008; 3: 453-72.
16. Filandi P, Paolillo S, Marciano C et al. Cardiovascular effects of ARV drugs: Clinical review. Cardiovasc Hematol Disord Drug Targets 2008; 8: 238-44.
17. Dhalla S, Chan K, Montaner J et al. Complementary and alternative medicine use in British Columbia - a survey of HIV positive people on antiretroviral therapy. Complement Ther Clin Pract 2006; 12: 242-8.
18. Ladenheim D, Horn O, Werneke U et al. Potential health risks of complementary alternative medicines in HIV patients. HIV Med 2008; 9: 653-9.
19. Park-Wyllie L, Levine M, Holbrook A et al. Outcomes of dosage adjustments used to manage antiretroviral drug interactions. Clin Infect Dis 2007; 45: 933-6.
20. Evans-Jones J, Cottle L, Khoo S et al. Physician awareness of antiretroviral drug interactions. In: Abstracts of the Fifteenth Annual Conference of the British HIV Association, Liverpool, UK, 2009 Abstract P138, p. 51. British HIV Association, London, UK.
21. Kigen G, Kimaiyo S, Back D et al. Prevalence of drug interactions between antiretroviral and co-administered drugs at the Moi teaching and referral hospital (Ampath), Eldoret, Kenya. In: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection, Glasgow, UK. Abstract O122. The International AIDS Society, Geneva, Switzerland. J Int AIDS Soc 2008; 11 Suppl 1: O7.
22. NHS Connecting for Health. Guidance for the NHS About Accessing Patient Information in New and Different Ways and What This Means for Patient Confidentiality. Version 1, 22 December 2006. www.connectingforhealth.nhs.uk (4 February 2009, date last accessed).
23. Pham P. Drug-drug interaction programs in clinical practice. Clin Pharmacol Ther 2008; 83: 396-8.
24. Magnus D, Rodgers S, Avery J. GPs' views on computerized drug interaction alerts: Questionnaire survey. J Clin Pharm Ther 2002; 27: 377-82.